What is Behavioral Diagnostics?
Behavioral Diagnostics operates at the intersection of biotechnology and artificial intelligence, focusing on the development of high-precision screening tools. By leveraging advanced epigenetic methodologies, the company provides actionable insights into substance addiction and oncology. Their core product suite, which includes the Lung CA Screening, Smoke Signature, and Alcohol Signature tests, serves a broad ecosystem of healthcare providers, insurers, and corporate employers. By prioritizing early detection, the company aims to shift the paradigm of cancer care from reactive treatment to proactive, data-driven prevention, thereby improving long-term patient outcomes and reducing systemic healthcare costs.
How much funding has Behavioral Diagnostics raised?
Behavioral Diagnostics has raised a total of $85K across 1 funding round:
Debt
$85K
Debt (2021): $85K with participation from PPP
Key Investors in Behavioral Diagnostics
PPP
Public-Private Partnership
What's next for Behavioral Diagnostics?
With this latest infusion of capital, Behavioral Diagnostics is poised to accelerate its commercialization efforts and expand its market footprint. The strategic focus will likely center on scaling the deployment of its epigenetic screening tests across clinical and corporate channels. As the company matures through its Series B/C stage, management is expected to prioritize the integration of its AI-driven risk assessment models into broader diagnostic workflows. Future growth will be contingent upon the successful adoption of these technologies by major insurance providers and the continued validation of their diagnostic accuracy in diverse patient populations, ultimately aiming to establish a new standard in preventative health diagnostics.
See full Behavioral Diagnostics company page
